Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJul 02, 2026
DataAggregated Company Financials
Companies9
  • 7D-0.5%
  • 3M3.5%
  • 1Y29.6%
  • YTD7.9%

The Pharma industry has stayed flat over the last week. As for the the longer term, the industry is up 30% over the past 12 months. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Jul 2026CHF 569.2bCHF 123.0bCHF 25.1b37.4x22.6x4.6x
Sat, 30 May 2026CHF 560.9bCHF 120.9bCHF 24.7b35.4x22.7x4.6x
Mon, 27 Apr 2026CHF 546.0bCHF 121.3bCHF 25.1b37.5x21.7x4.5x
Wed, 25 Mar 2026CHF 534.2bCHF 121.6bCHF 25.2b35.9x21.2x4.4x
Fri, 20 Feb 2026CHF 607.5bCHF 119.8bCHF 24.3b37.1x25x5.1x
Sun, 18 Jan 2026CHF 591.2bCHF 121.6bCHF 21.6b36.8x27.3x4.9x
Tue, 16 Dec 2025CHF 551.9bCHF 121.2bCHF 21.5b33.5x25.6x4.6x
Thu, 13 Nov 2025CHF 515.4bCHF 121.2bCHF 21.5b33.7x23.9x4.3x
Sat, 11 Oct 2025CHF 513.0bCHF 120.5bCHF 21.0b33.3x24.4x4.3x
Mon, 08 Sep 2025CHF 497.6bCHF 120.3bCHF 20.9b31.4x23.8x4.1x
Wed, 06 Aug 2025CHF 459.7bCHF 120.8bCHF 20.9b23x22x3.8x
Fri, 04 Jul 2025CHF 448.2bCHF 117.2bCHF 18.9b24.8x23.7x3.8x
Sun, 01 Jun 2025CHF 445.5bCHF 119.0bCHF 19.3b25.5x23.1x3.7x
Tue, 29 Apr 2025CHF 431.5bCHF 117.6bCHF 18.5b25.5x23.4x3.7x
Thu, 27 Mar 2025CHF 469.5bCHF 121.8bCHF 19.2b29.1x24.4x3.9x
Sat, 22 Feb 2025CHF 482.7bCHF 122.4bCHF 19.1b23.4x25.2x3.9x
Mon, 20 Jan 2025CHF 439.9bCHF 120.0bCHF 21.5b18.3x20.5x3.7x
Wed, 18 Dec 2024CHF 427.3bCHF 118.6bCHF 21.2b18.1x20.1x3.6x
Fri, 15 Nov 2024CHF 437.6bCHF 118.4bCHF 21.2b18.7x20.6x3.7x
Sun, 13 Oct 2024CHF 457.6bCHF 115.3bCHF 19.4b21.7x23.6x4x
Tue, 10 Sep 2024CHF 455.8bCHF 114.8bCHF 19.3b21.8x23.6x4x
Thu, 08 Aug 2024CHF 453.7bCHF 115.5bCHF 19.5b22.5x23.3x3.9x
Sat, 06 Jul 2024CHF 430.8bCHF 116.2bCHF 19.7b34.1x21.8x3.7x
Mon, 03 Jun 2024CHF 412.6bCHF 116.7bCHF 19.8b41.9x20.8x3.5x
Wed, 01 May 2024CHF 393.9bCHF 113.9bCHF 20.0b38.4x19.7x3.5x
Fri, 29 Mar 2024CHF 392.0bCHF 112.0bCHF 19.4b38.1x20.2x3.5x
Sun, 25 Feb 2024CHF 390.6bCHF 110.4bCHF 19.7b24.8x19.8x3.5x
Tue, 23 Jan 2024CHF 418.2bCHF 120.5bCHF 18.8b27.4x22.2x3.5x
Thu, 21 Dec 2023CHF 393.5bCHF 120.0bCHF 18.7b24.8x21x3.3x
Sat, 18 Nov 2023CHF 386.7bCHF 121.6bCHF 19.0b23.9x20.4x3.2x
Mon, 16 Oct 2023CHF 409.9bCHF 121.5bCHF 18.6b26.2x22x3.4x
Wed, 13 Sep 2023CHF 403.0bCHF 112.4bCHF 18.0b47.3x22.4x3.6x
Fri, 11 Aug 2023CHF 414.2bCHF 111.4bCHF 17.9b48.3x23.2x3.7x
Sun, 09 Jul 2023CHF 403.5bCHF 114.8bCHF 18.8b35.1x21.4x3.5x
Price to Earnings Ratio

21.4x


Total Market Cap: CHF 403.5bTotal Earnings: CHF 18.8bTotal Revenue: CHF 114.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 2.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-0.011%
Healthcare0.12%
Pharma-0.48%
Pharma-0.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 125.000.5%
+CHF 1.2b		27.0%PE20.9x
BIOV BioVersysCHF 27.001.1%
+CHF 1.8m		-24.8%PS49.8x
NWRN Newron PharmaceuticalsCHF 12.400.5%
+CHF 1.2m		76.1%PS14.6x
CURN Curatis HoldingCHF 22.300.9%
+CHF 1.0m		103.7%PS10.6x

Latest News

ROP
CHF 328.80
Roche Holding
7D
-1.0%
1Y
26.4%
NOVN
CHF 125.00
Novartis
7D
0.5%
1Y
27.0%
GALD
CHF 178.85
Galderma Group
7D
-2.6%
1Y
52.0%
SDZ
CHF 71.72
Sandoz Group
7D
-0.8%
1Y
68.3%
DESN
CHF 280.00
Dottikon ES Holding
7D
-0.5%
1Y
-7.1%
COPN
CHF 65.90
Cosmo
7D
-2.1%
1Y
11.1%
Narrative Update • Jun 22

COPN: European Dermatology Expansion Will Support CHF 160 Upside Potential

Analysts lifted their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple as key drivers of the change. What’s in the News for Cosmo Cosmo Pharmaceuticals N.V. reported that partners Glenmark Specialty S.A. and InfectoPharm launched Winlevi (clascoterone 1% cream) in key European markets, including Austria and Germany, following European Commission marketing authorization, according to recent company news.
CURN
CHF 22.30
Curatis Holding
7D
0.9%
1Y
103.7%
ADXN
CHF 0.041
Addex Therapeutics
7D
-1.9%
1Y
-33.5%
NWRN
CHF 12.40
Newron Pharmaceuticals
7D
0.5%
1Y
76.1%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 27.00
BioVersys
7D
1.1%
1Y
-24.8%